Drug delivery technologies for autoimmune disease

Expert Opinion on Drug Delivery

Volumn 7, Issue 11, 2010, Pages 1279-1289

  Phillips, Brett E ^a   Giannoukakis, Nick ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune; Drug delivery; Immunomodulation

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBODY; ANTIDIABETIC AGENT; BETA1A INTERFERON; BIIB 017; CERTOLIZUMAB PEGOL; DIAMYD; DIAPEP 277; ETANERCEPT; GLATIRAMER; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HYBRID PROTEIN; PEGADEMASE; PEGINTERFERON; POLYMER; PSORBAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; NONHUMAN; REVIEW; VIRUS RECOMBINANT;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; POLYMERS; TISSUE DISTRIBUTION;

EID: 77958555136     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.527329     Document Type: Review

References (100)

1. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
2. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16(3):342-50
3. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12(3):309-20
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-76
5. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50(3):701-8
6. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6(4):255-66
7. Johnson KP, Ford CC, Lisak RP, Wolinsky JS. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005;111(1):42-7
8. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2(5):347-60.
9. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2(3):214-21
10. Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv 2010;7(2):145-58
11. Monfardini C, Veronese FM. Stabilization of substances in circulation. Bioconjug Chem 1998;9(4):418-50
12. Nucci M, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev 1991;6(2):133-51
13. Davis FF. The origin of pegnology. Adv Drug Deliv Rev 2002;54(4):457-8
14. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-8.
15. Levy Y, Hershfield MS, Fernandez-Mejia C, et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr 1988;113(2):312-17
16. Herndon RM, Rudick RA, Munschauer FE III, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005;11(4):409-19
17. Efficacy and Safety Study of BIIB017 (ADVANCE). NIH 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00906399 [Last accessed August 2010]
18. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002;41(10):1133-7
19. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129(3):807-18
20. Goel N, Stephens S. Certolizumab pegol. MAbs 2010;2(2):137-47
21. Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006;8(1):R12
22. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 2007;119(2):236-44.
23. Hu W, Metselaar J, Ben LH, et al. PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS One 2009;4(1):e4151
24. Horisawa E, Kubota K, Tuboi I, et al. Size-dependency of DL-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res 2002;19(2):132-9
25. Ishihara T, Kubota T, Choi T, Higaki M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J Pharmacol Exp Ther 2009;329(2):412-17
26. Phillips B, Nylander K, Harnaha J, et al. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 2008;57(6):1544-55
27. Nguyen DN, Raghavan SS, Tashima LM, et al. Enhancement of poly (orthoester) microspheres for DNA vaccine delivery by blending with poly(ethylenimine). Biomaterials 2008;29(18):2783-93
28. Ebert EC. Infliximab and the TNF-alpha system. Am J Physiol Gastrointest Liver Physiol 2009;296(3):G612-20
29. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002;37(7):818-24
30. Mossner R, Reich K. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. Curr Probl Dermatol 2009;38:107-36
31. Kageyama Y, Takahashi M, Ichikawa T, et al. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26(1):73-80 (Pubitemid 351385258)
32. Olsen T, Cui G, Goll R, et al. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44(6):727-35
33. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124(7):1774-85
34. Brekke OH, Loset GA. New technologies in therapeutic antibody development. Curr Opin Pharmacol 2003;3(5):544-50
35. FDA. OKs two new uses for biologic arthritis drug adalimumab. Health News 2006;12(1):2
36. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158(6):2947-54
37. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91(1):123-7.
38. Makhlouf L, Grey ST, Dong V, et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation 2004;77(7):990-7
39. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54(6):1763-9
40. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 1998;12(12):1763-9, discussion 69-70, 75-7
41. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998;6(3):195-7
42. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572-81
43. Reis EA, Athanazio DA, Lima I, et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 2009;29(4):469-75
44. Suzuki K, Nagasawa H, Kameda H, et al. Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. Rheumatology (Oxford) 2009;48(2):198-9
45. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88
46. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007;117(12):3857-67
47. Xiu Y, Wong CP, Bouaziz JD, et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008;180(5):2863-75
48. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1-27
49. Alleva DG, Crowe PD, Jin L, et al. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001;107(2):173-80
50. Alleva DG, Gaur A, Jin L, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002;51(7):2126-34
51. Nicholson LB, Kuchroo VK. T cell recognition of self and altered self antigens. Crit Rev Immunol 1997;17(5-6):449-62
52. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19(4):238-46
53. Raz I, Avron A, Tamir M, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007;23(4):292-8
54. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358(9295):1749-53
55. Lazar L, Ofan R, Weintrob N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007;23(4):286-91
56. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999;21(1):75-87, discussion 1-2
57. Tikiz H, Arslan O, Pirildar T, et al. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis. Anadolu Kardiyol Derg 2010;10(2):98-103
58. Abramowicz Mark, Editor. Abatacept (Orencia) for rheumatoid arthritis Med Lett Drugs Ther 2006;48(1229):17-18
59. Dall'Era M, Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus 2004;13(5):372-6
60. A Study of Abatacept in patients with active ulcerative colitis. NIH 2006. Available from: http://clinicaltrials.gov/ct/show/NCT00410410 [Last accessed August 2010]
61. Intravenous CTLA4-lg treatment in recent onset type 1 diabetes mellitus. 2007. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00505375 [Last accessed August 2010]
62. Adams G, Vessillier S, Dreja H, Chernajovsky Y. Targeting cytokines to inflammation sites. Nat Biotechnol 2003;21(11):1314-20.
63. Smylie M, Blumenschein GR, Dowlati J, et al. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18S):7611
64. Tilstra J, Rehman KK, Hennon T, et al. Protein transduction: identification, characterization and optimization. Biochem Soc Trans 2007;35(Pt 4):811-15
65. Rothbard JB, Garlington S, Lin Q, et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 2000;6(11):1253-7
66. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008;1786(2):126-38
67. Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004;101(51):17867-72
68. Mi Z, Lu X, Mai JC, et al. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther 2003;8(2):295-305
69. Vocero-Akbani AM, Heyden NV, Lissy NA, et al. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999;5(1):29-33
70. Gould DJ, Favorov P. Vectors for the treatment of autoimmune disease. Gene Ther 2003;10(10):912-27
71. Hardy S, Kitamura M, Harris-Stansil T, et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997;71(3):1842-9
72. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996;93(24):13565-70
73. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990;87(6):2211-15
74. Oligino T, Ghivizzani S, Wolfe D, et al. Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther 1999;6(10):1713-20
75. Fang IM, Lin CP, Yang CH, et al. Inhibition of experimental autoimmune anterior uveitis by adenovirus-mediated transfer of the interleukin-10 gene. J Ocul Pharmacol Ther 2005;21(6):420-8
76. Shin S, Li N, Kobayashi N, et al. Remission of diabetes by beta-cell regeneration in diabetic mice treated with a recombinant adenovirus expressing betacellulin. Mol Ther 2008;16(5):854-61
77. Yamada K, Moriyama H, Okumachi Y, et al. Intravenous administration of proinsulin 1 or 2-expressing fiber-mutant recombinant adenovirus vector protects against the development of diabetes in NOD mice. Ann NY Acad Sci 2008;1150:183-6
78. Toh ML, Hong SS, van de Loo F, et al. Enhancement of adenovirus-mediated gene delivery to rheumatoid arthritis synoviocytes and synovium by fiber modifications: role of arginine-glycine-aspartic acid (RGD)- and non-RGD-binding integrins. J Immunol 2005;175(11):7687-98
79. Han G, Wang R, Chen G, et al. Gene delivery GAD 500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transduction efficiency do not play important roles. Immunol Lett 2008;115(2):110-16
80. Khoury M, Adriaansen J, Vervoordeldonk MJ, et al. Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med 2007;9(7):596-604
81. Khoury M, Courties G, Fabre S, et al. Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. Arthritis Rheum 2010;62(3):765-70
82. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129-38
83. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999;286(5448):2244-5
84. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001;107(10):1275-84
85. Nakajima A, Seroogy CM, Sandora MR, et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest 2001;107(10):1293-301
86. Creusot RJ, Yaghoubi SS, Kodama K, et al. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol 2008;127(2):176-87
87. Chen C, Rivera A, Ron N, et al. A gene therapy approach for treating T-cell-mediated autoimmune diseases. Blood 2001;97(4):886-94
88. Del Vecchio MA, Georgescu HI, McCormack JE, et al. Approaches to enhancing the retroviral transduction of human synoviocytes. Arthritis Res 2001;3(4):259-63
89. Wehling P, Reinecke J, Baltzer AA, et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther 2009;20:97-101
90. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(8):1006-12
91. Board of the European Society of Gene and Cell Therapy, Executive Committee of the Clinigene Network of Excellence, Executive of the Consert Integrated Project. Case of leukaemia associated with X-linked severe combined immunodeficiency gene therapy trial in London. Hum Gene Ther 2008;19(1):3-4
92. Bresson D, von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev 2007;6(5):315-22
93. Phillips B, Giannoukakis N, Trucco M. Dendritic cell-based therapy in Type 1 diabetes mellitus. Expert Rev Clin Immunol 2009;5(3):325-39
94. Hume DA, Ross IL, Himes SR, et al. The mononuclear phagocyte system revisited. J Leukoc Biol 2002;72(4):621-7
95. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007;7(1):19-30
96. Bluestone JA. Costimulation and its role in organ transplantation. Clin Transplant 1996;10(1 Pt 2):104-9
97. Kishimoto K, Dong VM, Sayegh MH. The role of costimulatory molecules as targets for new immunosuppressives in transplantation. Curr Opin Urol 2000;10(2):57-62
98. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005;80(5):555-63
99. Machen J, Harnaha J, Lakomy R, et al. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 2004;173(7):4331-41
100. Harnaha J, Machen J, Wright M, et al. Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes 2006;55(1):158-70